STOCK TITAN

Mizuho Americas Hires Graig C. Suvannavejh, PhD, as Senior Biopharmaceuticals and Biotechnology Analyst

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Mizuho Americas has appointed Graig Suvannavejh, PhD, as Managing Director and Senior Analyst in Biopharmaceuticals and Biotechnology Equity Research. Suvannavejh brings over 20 years of healthcare industry experience, including leadership roles in biotechnology research at Goldman Sachs. He will work alongside a well-established team and report to Susan Gilbertson, Head of US Equity Research. Mizuho Americas aims to enhance its financial services in the healthcare sector through Suvannavejh's expertise, which combines sell-side research with operational insights.

Positive
  • Dr. Suvannavejh's extensive experience in biopharmaceutical research could enhance Mizuho's market position.
  • His background in leading biotechnology research teams may provide fresh insights and strategies.
Negative
  • Potential concerns regarding continuity and the integration of new leadership within existing teams.

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Mizuho Americas today announced the hiring of Graig Suvannavejh, PhD, as Managing Director, Senior Biopharmaceuticals and Biotechnology Equity Research Analyst. Suvannavejh joins an experienced, global healthcare equity research team that includes US based Biotechnology Senior Analysts Mara Goldstein and Salim Syed, Biopharmaceuticals and Biotechnology Senior Analyst Vamil Divan and Analyst Uy Ear, Healthcare Services Senior Analyst Ann Hynes, with Barron Willard, Healthcare trader based in NY. The Japan based team includes Pharmaceuticals Analyst Hiroshi Tanaka, Pharmaceuticals and Biotechnology analyst Shinya Tsuzuki, and Medical Technologies and Services Analysts Takahiro Mori and Kazuki Furuyama.

Dr. Suvannavejh will be based in New York and report to Managing Director and Head of US Equity Research, Susan Gilbertson.

Dr. Suvannavejh has over 20 years of experience in healthcare which includes research roles at both bulge bracket and healthcare-dedicated boutique investment banks and corporate experience with operating roles in business development and strategy at top-tier global biopharmaceutical companies, including AbbVie and Biogen. He joins Mizuho from Goldman Sachs, where he successfully built out and led the European biotechnology research franchise there, and was a key player in the firm’s US biopharmaceuticals research efforts.

“Graig has a wealth of sell-side research analyst experience covering all verticals within the biopharma industry, which combined with his academic and industry operational expertise, allows him a unique and comprehensive perspective on the ever evolving biotech industry,” said Gilbertson. “He has the sensibilities of a scientist and the insights of an industry veteran. His expertise should advance Mizuho’s prominence in providing comprehensive financial services to healthcare issuers and investors.”

Dr. Suvannavejh holds a B.S. in Biology and an M.S. in Physiology & Biophysics from Georgetown University, and received his Ph.D. in Neuroscience from Northwestern University.

About Mizuho Americas

Mizuho Americas is a leading provider of a broad range of financial services, including corporate and investment banking, lending, custody, treasury services, research and capital markets solutions. With professionals across the U.S., Canada, and Latin and South America, Mizuho Americas supports corporate clients, institutional investors, and public sector organizations by connecting local markets to a vast global network. To learn more about Mizuho Americas' business, values, and ethical commitments, and the entities it comprises, visit www.mizuhogroup.com/americas. ​

Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE: MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services through its subsidiaries. The group has approximately 900 offices and 60,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. As of December 31, 2020, its total assets were $2.1 trillion. Learn more about Mizuho Financial Group at www.mizuhogroup.com​.

For inquiries, please contact:
Jim Gorman
Director, Media Relations, Mizuho Americas
+1-212-282-3867
jim.gorman@mizuhogroup.com

Laura London
Vice President, Media Relations, Mizuho Americas
+1-212-282-4446
laura.london@mizuhogroup.com


FAQ

What is the impact of Graig Suvannavejh's hiring on Mizuho Financial Group (MFG)?

Suvannavejh's expertise in biopharmaceuticals could improve Mizuho's financial services and competitive position in the healthcare sector.

What experience does Graig Suvannavejh bring to Mizuho Americas?

He has over 20 years of experience, including leadership roles at Goldman Sachs and top-tier biopharmaceutical companies like AbbVie and Biogen.

When did Mizuho Americas announce the hiring of Graig Suvannavejh?

The announcement was made on January 12, 2022.

What will be Dr. Suvannavejh's role at Mizuho Americas?

He will serve as Managing Director and Senior Analyst in Biopharmaceuticals and Biotechnology Equity Research.

Who will Dr. Suvannavejh report to at Mizuho Americas?

He will report to Susan Gilbertson, Managing Director and Head of US Equity Research.

Mizuho Financial Group, Inc. American Depositary Shares (Each representing one-fifth of an Ordinary Share)

NYSE:MFG

MFG Rankings

MFG Latest News

MFG Stock Data

60.70B
12.67B
1.09%
0.02%
Banks - Regional
Financial Services
Link
United States of America
Tokyo